Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

SOTALOL FOR SYSTEM SUITABILITY CRS (10 MG)

SOTALOL FOR SYSTEM SUITABILITY CRS (10 MG)

ND

DISCOVER
ETONOGESTREL CRS (100 MG)

ETONOGESTREL CRS (100 MG)

ND

DISCOVER
BRIVARACETAM CRS (160 MG)

BRIVARACETAM CRS (160 MG)

ND

DISCOVER
BRIVARACETAM IMPURITY A CRS (10 MG)

BRIVARACETAM IMPURITY A CRS (10 MG)

ND

DISCOVER
BRIVARACETAM IMPURITY B CRS (10 MG)

BRIVARACETAM IMPURITY B CRS (10 MG)

ND

DISCOVER
BRIVARACETAM IMPURITY C CRS (10 MG)

BRIVARACETAM IMPURITY C CRS (10 MG)

ND

DISCOVER
BRIVARACETAM IMPURITY D CRS (10 MG)

BRIVARACETAM IMPURITY D CRS (10 MG)

ND

DISCOVER
BRIVARACETAM IMPURITY E CRS (10 MG)

BRIVARACETAM IMPURITY E CRS (10 MG)

ND

DISCOVER
CABAZITAXEL FOR PEAK IDENTIFICATION CRS (10 MG)

CABAZITAXEL FOR PEAK IDENTIFICATION CRS (10 MG)

ND

DISCOVER
CABAZITAXEL IMPURITY FP-A CRS(10 MG)

CABAZITAXEL IMPURITY FP-A CRS(10 MG)

ND

DISCOVER
TEMAZEPAM FOR SYSTEM SUITABILITY CRS - * PSY (1.005 MG)

TEMAZEPAM FOR SYSTEM SUITABILITY CRS - * PSY (1.005 MG)

ND

DISCOVER
ETONOGESTREL IMPURITY MIXTURECRS (100 µL)

ETONOGESTREL IMPURITY MIXTURECRS (100 µL)

ND

DISCOVER